Positive mid-stage results for MS drug ocrelizumab
Positive mid-stage results for MS drug ocrelizumab
Roche Holding AG Friday said mid-stage trials of a experimental multiple sclerosis medicine ocrelizumab showed the drug to significantly reduce disease activity in patients with relapsing-remitting multiple sclerosis, raising hopes the medicine could make it to the market and eventually turn into a blockbuster.
Developed by U.S.-based Biogen Idec Inc (BIIB) and Roche unit Genentech, ocrelizumab was recently abandoned in treating patients suffering from rheumatoid arthritis due to an unfavourable risk profile, raising concerns the drug could be discarded in other indications, a step that would have weakened Roche’s pipeline...Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/
They are definitely moving this one along. I moved ocrelizumab to phase 3 on the pipeline list as they are starting a phase 3 trial for primary progressive MS.
http://www.clinicaltrials.gov/ct2/show/NCT01194570
http://www.clinicaltrials.gov/ct2/show/NCT01194570
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1013 Views
-
Last post by NHE
-
- 0 Replies
- 10755 Views
-
Last post by NHE
-
- 8 Replies
- 7322 Views
-
Last post by Algis
-
- 1 Replies
- 1199 Views
-
Last post by Scott1
-
- 1 Replies
- 1832 Views
-
Last post by frodo
-
- 0 Replies
- 1402 Views
-
Last post by NHE
-
- 0 Replies
- 442 Views
-
Last post by NHE
-
- 1 Replies
- 2867 Views
-
Last post by Tif
-
- 2 Replies
- 841 Views
-
Last post by DIM